RxDoctor Payments Data

Neil Manek, MD

Nephrology · Aurora, CONPI 1891950234

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,623 of the $7,697 with a category attached, or 60.1%. Calliditas Therapeutics US Inc. accounts for 62.0% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $3,349, 3.3 times the $1,001 reported in 2019.

$7,697in general payments, 2019–2025

Across 107 payments — averaging $71.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Calliditas Therapeutics US Inc.$5K
  • AstraZeneca$802
  • Otsuka America Pharmaceutical, Inc.$453
  • Vifor Pharma, Inc.$241
  • Fresenius USA Marketing, Inc.$167
  • Medtronic$147
  • plus $1K from 19 others

What the payments were for

  • Consulting fees$4,62360%
  • Food & beverage$3,05740%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,697 in reported general payments places this provider in the 85th percentile of 152 nephrology providers in Colorado.

See all nephrology providers in Colorado

Medicare billing

Part B allowed, 2024
$270,646
Medicare patients
286
Services billed
1,695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol88$90,555
JardianceEmpagliflozin98$89,598
EliquisApixaban25$22,218
KerendiaFinerenone16$17,383
LokelmaSodium Zirconium Cyclosilicate23$17,361
Sevelamer Carbonate15$3,024
Losartan Potassium103$1,199
Midodrine Hcl21$927
Chlorthalidone41$797
Hydralazine Hcl28$783
Lisinopril89$738
Amlodipine Besylate98$688
Potassium Chloride36$683
Calcitriol27$613
Carvedilol41$450

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$802$107,916111 claims
Boehringer IngelheimJardiance$130$89,59898 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 152 nephrology providers in Colorado.

Other nephrology in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →